耗竭型CD8+ T细胞亚群在肿瘤微环境中扩增并限制癌症免疫治疗
研究采用单细胞质谱流式与组织成像技术,分析25例可切除和35例晚期非小细胞肺癌患者的肿瘤浸润淋巴细胞,鉴定出一个在肿瘤微环境中特异性积聚的耗竭型CD8+ T细胞亚群(Ebo)。该亚群增殖和活化标志物表达最高但IFNγ产生最少且凋亡最多,其扩增依赖PD-1/B7-H1通路,基线丰度与抗PD治疗耐药相关。
要点
- 鉴定出区别于经典耗竭T细胞的耗竭型CD8+ T细胞亚群Ebo。
- Ebo在肿瘤微环境中特异性积聚,增殖活化高但功能低且凋亡多。
- Ebo基线丰度与NSCLC患者抗PD治疗耐药相关。
核心结论
- 肿瘤微环境中存在一个高增殖、过度活化且凋亡的功能障碍CD8+ T细胞亚群Ebo,其扩增依赖PD-1/B7-H1通路,基线丰度与抗PD治疗耐药相关。
研究设计与样本
- 采用单细胞质谱流式和组织成像技术,分析25例可切除和35例晚期非小细胞肺癌患者的肿瘤浸润淋巴细胞。
- 使用人源化患者来源肿瘤异种移植模型验证Ebo扩增机制。
主要发现
- Ebo在肿瘤微环境中特异性积聚,而在邻近非肿瘤组织中不积聚。
- Ebo增殖和活化标志物表达最高,但IFNγ产生量最低,且是最易凋亡的CD8+ TIL亚群。
- Ebo扩增在肿瘤微环境中以PD-1/B7-H1通路依赖方式发生。
- 基线肿瘤组织中Ebo丰度与NSCLC患者抗PD治疗耐药相关。
临床怎么用
- Ebo丰度可作为潜在的组织生物标志物,用于评估NSCLC患者抗PD治疗耐药风险。
- 针对Ebo亚群的特征,可能为克服免疫治疗耐药提供新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Specific mechanisms by which tumor-infiltrating lymphocytes (TIL) become dysfunctional remain poorly understood. Here, we employed a two-pronged approach using single-cell mass cytometry and tissue imaging technologies to dissect TILs from 25 patients with resectable and 35 patients with advanced non-small cell lung cancer (NSCLC). We identified a burned-out CD8+ TIL subset (Ebo) that specifically accumulated within the tumor microenvironment (TME) but not in adjacent nontumoral tissues. Ebo showed the highest expression of proliferation and activation markers but produced the lowest amount of IFNγ and were the most apoptotic CD8+ TIL subset. Using a humanized patient-derived tumor xenograft model, we demonstrated that Ebo expansion occurred within the TME in a PD-1/B7-H1 pathway-dependent manner. Ebo abundance in baseline tumor tissues was associated with resistance to anti-PD therapy in patients with NSCLC. Our study identifies a dysfunctional TIL subset, with distinct features from previously described exhausted T cells, and implies strategies to overcome immunotherapy resistance. SIGNIFICANCE: We identified a highly proliferative, overactivated, and apoptotic dysfunctional CD8+ tumor-infiltrating subpopulation that is functionally distinct from previously described exhausted T cells. This population is expanded in lung cancer tissues in a PD-1/B7-H1-dependent manner, and its abundance is associated with resistance to cancer immunotherapy, thus becoming a potential tissue biomarker.This article is highlighted in the In This Issue feature, p. 1601.
引用
- Sanmamed MF, Nie X, Desai SS, et al. A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy. Cancer Discov. 2021. PMID: 33658301. doi:10.1158/2159-8290.CD-20-0962
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。